How did the introduction of mifepristone impact the availability of abortion care in Ottawa? A qualitative study with abortion patients

• Main Authors: Kathryn J. LaRoche, Isabelle N. Labeca-Gordon, Angel M. Foster
• Format: Article
• Language: English
• Published: Canadian Science Publishing 2020-07-01
• Series: FACETS
• Subjects: canada; health services; medication abortion; mifepristone; patient experiences
• Online Access: https://www.facetsjournal.com/doi/full/10.1139/facets-2020-0019

In 2017, mifepristone and misoprostol became available for early pregnancy termination as the combination pack Mifegymiso® in Ottawa, Ontario, Canada. We conducted 40 semi-structured telephone interviews with Ottawa residents who had abortions before mifepristone’s introduction (n = 20) and after mifepristone–misoprostol became available (n = 20) to explore their experiences obtaining care. We audio-recorded and transcribed all interviews and analyzed these data for content and themes using deductive and inductive techniques. Prior to the introduction of mifepristone, our participants reported obtaining abortion care at two facilities and many faced long wait times. Those who had an abortion after mifepristone became available reported obtaining care from a wider array of providers and few waited more than two weeks. However, several mifepristone–misoprostol users reported having to go through a process that involved as many as 10 health service encounters. Both groups reflected positively on their abortion experiences, but some patients who obtained mifepristone–misoprostol outside of an abortion clinic did not feel as well informed as they would have liked. The introduction of mifepristone appears to have expanded the number of service delivery points and reduced wait times for those seeking abortion care in Ottawa. Identifying ways to expand access to medication abortion information and streamline services appears warranted.